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A B S T R A C T
Background
There is conflicting information about the impact of the menopause on glycaemic control amongst women with type 1 diabetes. Some
menopausal women with type 1 diabetes are treated with hormone replacement therapy (HRT) but the effects of this treatment have,
to date, not been established.
Objectives
To assess the effects of HRT for women with type 1 diabetes mellitus.
Search methods
We searched The Cochrane Library, MEDLINE, EMBASE, CINAHL and PsycINFO from their inception to June 2012. The last
search was run for all databases on 18 June 2012.
Selection criteria
We selected randomised controlled trials or controlled clinical trials that involved peri- or postmenopausal women with type 1 diabetes
undergoing HRT as an intervention.
Data collection and analysis
Two researchers independently applied the inclusion criteria to the identified studies and assessed risk of bias. Disagreements were
resolved by discussion or by intervention by a third party. Descriptive analysis was conducted for the review.
Main results
Ninety-two publications were screened. No studies met the inclusion criteria exclusively but one study that included both type 1 and
type 2 diabetes participants was considered. This randomised clinical trial (RCT) compared HRT (N = 27) with placebo (N = 29)
over 12 months. The outcome measures were cardiovascular risk factors, including lipid profile, glycaemic control, blood pressure and
body weight. No significant differences between placebo and HTR were detected. Patient-important outcomes like all-cause mortality,
cardiovascular disease, diabetic complications or health-related quality of life were not investigated.
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Authors’ conclusions
There is a lack of evidence around the use of HRT in women with type 1 diabetes. The one study that has been undertaken in this
area is underpowered. More RCTs are required in the area to examine the impact of HRT on glycaemic control and cardiovascular
outcomes.
P L A I N L A N G U A G E S U M M A R Y
Hormone replacement therapy for women with type 1 diabetes mellitus
There are increasing numbers of people living with type 1 diabetes mellitus. The main aim of treatment for diabetes is to maintain
good quality of life and to minimise, or prevent, the development of diabetic complications by controlling blood glucose levels.Women
with type 1 diabetes frequently express difficulties in controlling their blood glucose levels during the menopausal phase of their lives.
However, the cause of this has not been explored.
Hormone replacement therapy is a treatment that is prescribed tomanywomen to alleviate the symptoms associatedwith themenopause.
The literature surrounding hormone replacement therapy and type 1 diabetes has never been systematically searched and reviewed.
The evidence available for healthcare professionals to call upon relating to the management of menopausal women with type 1 diabetes
is vague. There is conflicting literature regarding the use of hormone replacement therapy in women with type 1 diabetes, as many of
the studies also included women with type 2 diabetes. We found one study with a type 1 diabetes subgroup involving 56 participants
receiving either hormone replacement therapy or placebo over 12 months. No statistically significant differences were found between
hormone replacement therapy and placebo. Patient-important outcomes like death from any cause, cardiovascular disease (for example,
heart attack, stroke), diabetic complications (for example, diabetic eye disease, diabetic kidney disease) or health-related quality of life
were not investigated.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Hormone replacement therapy compared with placebo for women with type 1 diabetes mellitus
Patient or population: peri- or postmenopausal women with type 1 diabetes mellitus
Settings: outpat ients
Intervention: hormone replacement therapy ((oestrogen (17B-oestradiol, 2 mg) and progesterone (norethisterone acetate, 1
mg))
Comparison: placebo
Outcomes No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Diabetes and non-diabetes
related morbidity
See comment See comment Not invest igated
Death from any cause See comment See comment Not invest igated
Adverse effects
[f ollow-up: 12 months]
56
(1)
⊕©©©
very lowa
Most f requent ly reported
event was breast pain (37 type
1 diabetes mellitus and type 2
diabetes mellitus part icipants
on hormone replacement ther-
apy (HRT) versus nine placebo
part icipants); vaginal bleeding
occurred in 26 HRT versus
three placebo part icipants
Health- related quality of life See comment See comment Not invest igated
Glycaemic control (fruc-
tosamine levels)
[f ollow-up: 12 months]
56
(1)
⊕©©©
very lowa
No stat ist ically signif icant dif -
ferences between intervent ion
and comparator groups
Economic data See comment See comment Not invest igated
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and
may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is
likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aDue to very serious indirectness, serious risk of bias, low number of part icipants and studies
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B A C K G R O U N D
Description of the condition
Diabetes mellitus is a metabolic disorder resulting from a defect in
insulin secretion, insulin action, or both. A consequence of this is
chronic hyperglycaemia (that is elevated levels of plasma glucose)
with disturbances of carbohydrate, fat and protein metabolism.
Long-term complications of diabetes mellitus include retinopathy,
nephropathy and neuropathy. The risk of cardiovascular disease
and cancer is increased.
It is acknowledged that there is an increasing number of people
who suffer from type 1 diabetes (Diabetes UK 2006). The main
aims of treatment for type 1 diabetes are to maintain good health-
related quality of life and to minimise, or prevent, the microvascu-
lar andmacrovascular complications caused by the disease through
good glycaemic control (Norris 2001; Signuroardottir 2005). A
major trial has demonstrated conclusively that optimal glycaemic
control can improve the physical and psychological well-being of
people with type 1 diabetes (DCCT 1993). Physiological changes
like pregnancy, weight gain, puberty and psychological issues like
stress are known to affect glycaemic control (Russel 2001;Weinger
2001). It is well recognised that changes in sex hormones can in-
crease insulin resistance during puberty and pregnancy (Dahlgren
2006). These findings imply that during themenopause awoman’s
requirement for insulin will be altered.
The menopause is a stage in the female reproductive cycle that
occurs as the ovaries stop producing oestrogen causing the repro-
ductive system to cease functioning (Freeman 2007). As the body
adapts to changing levels of natural hormones various symptoms
may be experienced.These include amongst others: (1) hot flushes,
palpitations, night sweats, (2) mood swings, lack of concentra-
tion, (3) vaginal dryness, decreased libido, (4) weight changes. To
overcome some of these symptoms hormone replacement therapy
(HRT) can be prescribed. There is emerging evidence about the
benefits and disadvantages of HRT in women with type 1 dia-
betes (Andersson 2000; Smith 2000). Insulin resistance can be
modified by HRT but to date much of the evidence relating to
HRT in diabetes has been extrapolated from non-diabetic women.
There is some evidence that women with diabetes have a blunted
response to the beneficial effects of HRT on lipids (Robinson
1996).Women with diabetes are at increased risk of cardiovascular
disease with the pathogenesis linked to insulin resistance (Satter
1996). Interestingly, HRT has been found to be prescribed less in
women with diabetes than in women without diabetes (Progetto
Menopausa Italia Study Group 2001). However, no link has been
found between the use of HRT and mortality in a longitudinal
study of women with diabetes in the US (Klein 1999), while there
is a suggestion that glycosylated haemoglobin may be significantly
decreased inwomenwith type 2diabeteswho take postmenopausal
oestrogen (Brussaard 1992).
The experience and management of the menopause amongst
women is unique and at times complex. It is proposed that for
women with type 1 diabetes managing the menopause is more
complex due to changes in their physical and psychological sta-
tus impacting on their glycaemic control. These women usually
have an earlier onset of menopause than women without diabetes
(Zarzycki 2005). From practice it is known that often women
confuse the signs of the menopause with hypoglycaemia. Both
of these physiological changes can result in night sweats, mood
changes and palpitations; therefore, it is difficult for the women
to distinguish whether they are suffering from hypoglycaemia or
experiencing menopausal symptoms. Interestingly, clinical experi-
ence suggests that menopausal women are sometimes inappropri-
ately treating their perceived hypoglycaemic symptoms resulting
in hyperglycaemia.
Additionally, some people are administering HRT to alleviate
symptoms of the menopause but the effectiveness of this inter-
vention has not been clearly established. In addition to the signs
and symptoms of the menopause being confused by women with
the symptoms of hypoglycaemia causing possible inappropriate
insulin use, alterations in diet, weight and mood sometimes ex-
perienced during the menopause can also necessitate changes in
insulin use. Overall, this can necessitate women to alter their self-
management regimen significantly which can cause further phys-
ical and psychological stress.
The evidence available to patients and healthcare professionals
surrounding the management of menopausal women with type 1
diabetes and health-related quality of life issues is vague. There is
conflicting literature surrounding the use of HRT in women with
type 1 diabetes and this literature has never been systematically
searched, retrieved and reviewed.
Description of the intervention
The intervention under investigation is HRT versus no hormone
therapy in women with type 1 diabetes.
For many years, oestrogen alone or in combination with pro-
gestogens, otherwise known as HRT, has been the treatment of
choice for control of problematic menopausal symptoms and for
the prevention of osteoporosis. A recent publication from the
International Menopause Society 2008 has stated that HRT re-
mains the first-line and most effective treatment for menopausal
symptoms. The use of HRT in all women has declined after
the publication of several studies which linked the treatment
to increased risk of breast cancer (Beral 2003; Women’s Health
Initiative Investigators 2002), coronary heart disease (Women’s
Health Initiative Investigators 2002) and venous thromboem-
bolism (Hulley 2002).
HRT should currently only be prescribed for menopausal symp-
toms and not for prevention of osteoporosis or cardiovascular dis-
ease. It is currently recommended that the lowest dose of HRT
based on relieving menopausal symptoms should be prescribed
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(Khoo 2005). Oral HRT regimens are well tolerated and are con-
sidered as first-line therapy in most women. There is significant
individual variation in response to HRT and it is often appropri-
ate to try two or three different preparations. Women should be
encouraged to persevere with a new preparation for two to three
months as any side-effects experienced initially may settle with
time.Women should be reviewed three months after commencing
therapy. The ongoing need for HRT should be reassessed at least
annually. Blood pressure should be checked 6 to 12 monthly, and
each woman encouraged to attend cervical and breast screening
programmes. Breast awareness should be encouraged. Stopping
HRT abruptly can cause some women to have hot flushes and it
should, therefore, be withdrawn gradually by decreasing dosages
over three to six months.
HRT is contra-indicated in the presence of active venous throm-
boembolism, unexplained vaginal bleeding, oestrogen dependent
tumours (breast and endometrial cancer), current or recent cardio-
vascular disease and acute porphyria. Women who have not had a
hysterectomy should be commenced on a sequential or continuous
combined form of HRT starting at the lowest dose available and
increasing if required to give symptom control. Continuous com-
bined therapy (period-free HRT) should only be used by women
who are at least a year past the menopause or over 54 years of age.
Both oestrogen and progestogen are taken daily to give a period-
free regimen. Erratic bleeding is common in the first few months
of use. For women who have had a hysterectomy unopposed oe-
strogens should be prescribed.
Possible and known adverse effects of the intervention
Glycaemic control
Studies have indicated that HRT appears to lower glycaemic con-
trol as indicated by glycosylated haemoglobin A1c (HbA1c) in
women who have type 2 diabetes. HRT users have a lower than av-
erage HbA1c than non-HRT users (Ferrara 2001). Furthermore,
current HRT users may experience better glycaemic control than
those who have never used it or who had previously done so
(Crespo 2002). Both these studies indicate that glycaemic control
is affected and can be improved in women who have type 2 dia-
betes taking HRT.
To our knowledge the relationship between HRT and glycaemic
control has not been investigated in type 1 diabetes.
Changes in insulin sensitivity
Studies involving women with type 2 diabetes indicate that oestra-
diol given orally or transdermally tends to improve insulin sen-
sitivity (Cagnacci 1992). However, it has also been shown that a
dose of 1.25 mg/day reduces insulin sensitivity (Ajabor 1972).
Combining HRT with progestogen may reduce insulin sensitivity
(Lindheim 1993). Furthemore, high doses of approximately 20
mg have no effect on insulin sensitivity, with lower doses of 10mg/
day leading to a decrease in insulin concentrations (Crook 1997).
To our knowledge the relationship between HRT and changes in
insulin sensitivity has not been investigated in type 1 diabetes.
Health-related quality of life
The provision of information, education and psychological sup-
port to facilitate self management are essential components of dia-
betes care and are known to improve health-related quality of life.
The interpretation of the data on the effect of HRT on health-re-
lated quality of life varies, with theWISDOMstudy showing mea-
surable improvements in health-related quality of life, sexuality
and joint pain in symptomatic women (Welton 2008); however,
women with diabetes were not investigated separately. HRT has
been found to be efficacious in comparison with placebo in reduc-
ing the frequency and severity of hot flushes in healthymenopausal
women (MacLennan 2004).
Coronary heart disease (CHD)
The Women’s Health Initiative study (Women’s Health Initiative
Investigators 2002) showed an increase in CHD events from 30 to
37 cases per 10,000 treated women. However, more recent studies
have suggested that HRT does not cause an increase in CHD risk
and may have a cardioprotective role in younger women in the
early postmenopausal years (Rossouw 2007). Whether this is the
case in women with type 1 diabetes is unclear.
Venous thromboembolism (VTE)
While the risk of VTE with HRT remains low, a two-fold increase
in VTE has been found when standard doses of oral HRT are
compared to placebo (Cushman 2004). Healthy postmenopausal
women are at low risk of VTE but the use of HRT is best avoided
in women with a previous history of VTE.
Ovarian cancer
While theMillionWomen Study collaborators found an increased
risk of ovarian cancer in women using HRT compared to women
who had never used HRT, the risks were ’small’ (one extra case of
cancer in 2500 users of HRT) with the risk falling back to pre-use
levels when the HRT was discontinued (Million Women Study
Collaborators 2007).
Breast cancer
The effects ofHRTonbreast cancer appear to be related to the type
of HRT and the duration of the therapy with combined oestrogen
and progesterone therapy taken over five years demonstrating the
greatest risk. TheWomen’s Health Initiative showed an increase in
breast cancer of eight cases per 10,000 treated women (Women’s
Health Initiative Investigators 2002).
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Reduced bone mineral density
HRT has a beneficial effect on bone mineral density with the large
studies (Women’s Health Initiative Investigators 2002) showing
HRTwas effective in preventing fractures secondary to osteoporo-
sis.
Why it is important to do this review
There is currently some ambiguity surrounding the use of HRT
in women with type 1 diabetes . The current literature offers con-
flicting information making clinical decisions problematic. There
have been no systematic reviews of the evidence for methods re-
lating to the impact of HRT on menopausal women with type
1 diabetes undertaken to date. This information is necessary to
guide professionals when they are considering how best to em-
power women to manage their diabetes during this stage in their
life and also to inform future studies on this group.
O B J E C T I V E S
To assess the effects of hormone replacement therapy for women
with type 1 diabetes mellitus.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and controlled clinical trials
(CCTs).
Types of participants
Peri- and postmenopausal women with type 1 diabetes.
Types of interventions
Intervention
• Hormone replacement therapy for women with type 1
diabetes mellitus.
Control
• Placebo.
• No intervention.
• Usual care.
Types of outcome measures
Primary outcomes
• Glycaemic control (glycosylated haemoglobin A1c
(HbA1c), blood glucose levels (self monitored)).
• Diabetes and non-diabetes related morbidities.
• Health-related quality of life (using validated instruments).
Secondary outcomes
• Total daily insulin dosage.
• Body mass index (BMI), weight.
• Frequency and severity of hypoglycaemia.
• Death from any cause.
• Adverse effects.
• Economic data.
Covariates, effect modifiers and confounders
• Duration of diabetes.
• Compliance with treatment.
• Diabetes management skills.
• Presence of diabetes complications.
• Age.
• Level of physical activity.
Timing of outcome measurement
Short term (less than six months)
• Glycaemic control.
• Total daily insulin dose.
• Diabetes and non-diabetes related morbidities.
• Averse effects.
Medium term (six to 12 months)
• Diabetes and non-diabetes related morbidities.
• Health-related quality of life.
• Adverse effects.
• BMI, weight or both.
Long term (more than 12 months)
• Diabetes and non-diabetes related morbidities.
• Adverse effects.
• Death from any cause.
• Economic data.
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Search methods for identification of studies
Electronic searches
We used the following sources from inception until specified date
for the identification of trials.
• The Cochrane Library (issue 3, 2012).
• MEDLINE (until June 2012).
• EMBASE (until June 2012).
• CINAHL (until June 2012).
• PsycINFO (until June 2012).
For detailed search strategies please see under Appendix 1.
The ISI Web of Knowledge database was searched for relevant
abstracts from conference proceedings. We also searched databases
of ongoing trials: ’Current Controlled Trials’ (www.controlled-
trials.com - with links to other databases of ongoing trials).
Additional keywords of relevance could have been detected during
any of the electronic or other searches. In this case, we would have
modified electronic search strategies to incorporate these terms.
We planned to include studies published in any language.
Searching other resources
We tried to identify additional studies by searching the reference
lists of included trials and systematic reviews, meta-analyses and
health technology assessment reports. Potential missing and un-
published studies were sought by contacting expert authors in the
field.
Data collection and analysis
Selection of studies
To determine the studies to be assessed further, two review authors
(LK, JC) independently reviewed the abstracts, title or both sec-
tions of every record retrieved. All potentially relevant articles were
investigated as full text. Only one study was identified as being
suitable for inclusion. An adapted PRISMA (preferred reporting
items for systematic reviews and meta-analyses) flow-chart (see
Figure 1) of study selection is attached (Liberati 2009).
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Figure 1. Study flow diagram.
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Data extraction and management
Two review authors (LK, JC) independently abstracted relevant
population and intervention characteristics using standard data
extraction templates (for details see ’Characteristics of included
studies’; Table 1; Appendix 2; Appendix 3; Appendix 4; Appendix
5; Appendix 6) with any disagreements to be resolved by discus-
sion, or if required, by a third party. We sought any relevant miss-
ing information on the trial from the original author(s) of the ar-
ticle, if required.
Assessment of risk of bias in included studies
Two authors (LK, JC) assessed the one trial independently.
We assessed risk of bias using The Cochrane Collaboration’s tool
(Higgins 2011). We used the following criteria.
• Was the allocation sequence adequately generated?
• Was the allocation adequately concealed?
• Was knowledge of the allocated intervention adequately
prevented during the study?
• Were incomplete outcome data adequately addressed?
• Were reports of the study free of suggestion of selective
outcome reporting?
• Was the study apparently free of other problems that could
put it at a high risk of bias?
A judgement of ‘Yes’ indicates low risk of bias, ‘No’ indicates high
risk of bias and ‘Unclear’ indicates unclear or unknown risk of bias.
We used these criteria for a judgement of ‘Yes’, ‘No’ and ‘Unclear’
for individual bias items as described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
We planned to assess the impact of individual bias domains on
study results at endpoint and study levels.
Measures of treatment effect
We planned to express dichotomous data as odds ratios (ORs) or
risk ratios (RRs) with 95% confidence intervals (CIs). We planned
to express continuous data as mean differences (MD) with 95%
CI.
Unit of analysis issues
We planned to take into account the level at which randomisation
occurred, such as cross-over trials, cluster-randomised trials and
multiple observations for the same outcome.
Dealing with missing data
Wewanted to obtain relevantmissingdata fromauthors, if feasible,
and planned to perform evaluation of important numerical data
such as screened, randomised patients, as well as intention-to-
treat (ITT) and per protocol (PP) populations. We planned to
investigate attrition rates, for example, drop-outs, losses to follow-
up, withdrawals. We also wanted to critically appraise issues of
missing data and techniques to handle these (for example, last-
observation-carried-forward (LOCF)).
Assessment of heterogeneity
In the event of substantial clinical or methodological or statistical
heterogeneity we planned not to report study results as meta-an-
alytically pooled effect estimates. We planned to identify hetero-
geneity by visual inspection of forest plots, by using a standard Chi
2 test and a significance level of α = 0.1, in view of the low power
of this test. We wanted to specifically examine heterogeneity with
the I2 statistic quantifying inconsistency across studies to assess
the impact of heterogeneity on the meta-analysis (Higgins 2002),
where I2 values of 50% and more indicates a considerable level of
inconsistency (Higgins 2003).
When heterogeneity was found, we planned to determine poten-
tial reasons for it by examining individual study and subgroup
characteristics.
Assessment of reporting biases
We planned to use funnel plots to assess for the potential existence
of small study bias. There are a number of explanations for the
asymmetry of a funnel plot (Sterne 2011). Therefore, we planned
to carefully interpret results (Lau 2006).
Data synthesis
We planned to summarise data statistically if they were available,
sufficiently similar and of sufficient quality. We would have per-
formed statistical analyses according to the statistical guidelines
referenced in the most recent version of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses and
wanted to investigate interaction.
• Post- and perimenopause.
• Type of HRT (oestrogen only, combined oestrogen and
progesterone).
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Sensitivity analysis
We planned to perform sensitivity analyses in order to explore the
influence of the following factors on effect sizes.
• Restricting the analysis to published studies.
• Restricting the analysis taking into account risk of bias, as
specified above.
• Restricting the analysis to very long or large studies to
establish how much they dominate the results.
• Restricting the analysis to studies using the following filters:
diagnostic criteria, language of publication, source of funding
(industry versus other), country.
We also planned to test the robustness of the results by repeating
the analysis using different measures of effect size (RR, OR etc.)
and different statistical models (fixed-effect and random-effects
models).
R E S U L T S
Description of studies
For a detailed description of studies, see Tables ’Characteristics of
included studies’ and ’Characteristics of excluded studies’.
Results of the search
The initial search identified 92 records. After removal of duplicates
and reviewof the 87 titles and available abstracts, four potential full
text articles and theses were identified for further assessment. Only
one study met the inclusion criteria of the review. We excluded
the other studies on the basis of their titles or abstracts because
they did not meet the inclusion criteria or were not relevant to the
question under study or were a duplicate report (see Figure 1 for
the amended PRISMA (preferred reporting items for systematic
reviews and meta-analyses) flow chart).
Included studies
The details of the included study (Scott 2004) are described in
the ’Characteristics of included studies’ table and appendices. This
was a randomised controlled study, although the randomisation
process was not stated. Study duration was 12 months.
Participants and setting
The included study involved postmenopausal women who had
type 1 or type 2 diabetes. Stratification was conducted based on
the type of diabetes. Both the type 1 (T1DM) and type 2 diabetes
(T2DM) groups consisted of a hormone replacement intervention
(HRT) and comparator (placebo) arm. After an initial six week
run-in period, participants were randomly allocated to HRT or
placebo. Mean age for the HRT group was 60 years and for the
placebo groupwas 59 years.Of the original total (includingT1DM
and T2DM) of 150 women, 55 withdrew throughout the study,
with themain reasons being due to adverse effects or persistence of
menopausal symptoms. Data describing the percentage of drop-
out relating to type of diabetes were not provided. The included
trial’s baseline characteristics are stated in Appendix 3.
Interventions
The intervention group receivedHRT(oestrogen (17B-oestradiol)
and progestogen (norethisterone acetate, 1mg)), while the placebo
controlled group did not (placebo not described). The description
of the intervention for the included trial’s is shown in Appendix
2.
Outcomes
The details of the outcomes are stated in the ’Characteristics of
included studies’ and Appendix 4.
Excluded studies
There were three studies excluded from the review. The reasons
for exclusion were due to non-type 1 diabetes participants, non-
HRT intervention used, or participants were not menopausal (see
’Characteristics of excluded studies’).
Risk of bias in included studies
For details on the methodological quality of the included study
see ’Characteristics of included studies’.
Effects of interventions
See: Summary of findings for the main comparison
Baseline characteristics
For details of baseline characteristics, see Appendix 3.
Primary outcomes
No interaction between type of diabetes (T1DM or T2DM) and
treatment (HRT or placebo) achieved statistical significance for
any of the variables analysed. Study authors pooled all results by
combining all diabetes participants.
Diabetes and non-diabetes related morbidities and health-related
quality of life were not investigated.
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Glycaemic control
Glycaemic control (measuring fructosamine) showed no statisti-
cally significant treatment effect (P = 0.27) or effect of type of
diabetes (P = 0.45).
Secondary outcomes
No interaction between type of diabetes (T1DM or T2DM) and
treatment (HRT or placebo) achieved statistical significance for
any of the variables analysed. Study authors pooled all results by
combining all diabetes participants.
Death from any cause, frequency and severity of hypoglycaemia,
body mass index, weight, total daily insulin dosage and economic
data were not investigated.
Adverse effects
HRTwas associated with more adverse events: themost frequently
reported event was breast pain (37 HRT T1DM and T2DM par-
ticipants versus nine placebo participants); vaginal bleeding oc-
curred in 26 HRT versus three placebo participants.
Other outcomes
Other investigated outcomes of the included study were cardio-
vascular risk factors. Low-density lipoprotein (LDL) fell in both
treatment groups. The difference between treatment groups was
not significant (0.14 mmol/L; 95% CI -0.44 to +0.17; P = 0.37).
High-density lipoprotein (HDL) were significantly lower with
HRT than placebo (-0.2; 95% CI -0.28 to -0.11; P < 0.001). Sub-
group analysis between T1DM and T2DM showed a decrease in
mean HDL in T1DM only.
D I S C U S S I O N
Summary of main results
The main finding from the single study (Scott 2004) identified
through our search indicates that hormone replacement therapy
(HRT) may not worsen glycaemic control in women with type 1
diabetes. This finding is in agreementwith previous studies involv-
ing women who have type 2 diabetes (Crespo 2002; Ferrara 2001).
However, there are limitations in the Scott 2004 study that must
be considered. No pre- or post-intervention information regard-
ing glycosylated haemoglobin A1c (HbA1c) change was provided,
which presents a limitation if the effects of HRT and glycaemic
control are to be understood. In addition, no information regard-
ing insulin regimen was provided, nor was there any information
relating to the amount of exogenous insulin taken. Therefore, it
is not clear if the study participants in Scott 2004 altered their
insulin intake throughout the study.
The complexity surrounding HRT and its affects on many of the
physiological responses in women with diabetes are considerable.
For example, womenwith type 1diabetes tend to experience symp-
toms of menopause earlier than women without diabetes, which
can potentially lead to a reduction in reproductive years (Dorman
2001). Furthermore, menstrual irregularities are reported more
frequently in women with type 1 diabetes thanwomen without di-
abetes and they particularly appear to have difficulty in controlling
blood glucose levels around the time of menstruation (Strotmeyer
2006). It is perhaps not surprising that as a consequence, due to
the lack of empirical evidence detailing the effects of HRT on
glycaemic control, evidence-based guidelines on how to manage
glycaemia during the menopause for women with type 1 diabetes
are unavailable.
Thus, information regarding how HRT affects glycaemic control
in women with type 1 diabetes is unclear. Studies which have
reported glycaemic effects are limited (Scott 2004) and are often
hampered by small sample sizes (Dorman 2001).
The key finding of this review is that HRT does not appear to
worsen glycaemic control in women with type 1 diabetes. How-
ever, as previously discussed, findings from that study must be
taken with caution given the study limitations.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently a lack of evidence regarding the use of hormone
replacement therapy amongst menopausal women with type 1 di-
abetes. HRT may impact upon glycaemic control and cardiovas-
cular risk of women with type 1 diabetes but this review cannot
make any recommendations for practice.
Implications for research
Research to examine this topic needs to be undertaken to inform
future practice. Randomised controlled trials to measure the im-
pact of HRT on glycaemic control and cardiovascular risk factors
in women with type 1 diabetes are possible. Descriptive and qual-
itative studies would be beneficial to examine the impact of HRT
from the healthcare professional and patient perspectives.
A C K N OW L E D G E M E N T S
None.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Scott 2004
Methods Randomised controlled clinical trial
Participants Inclusion criteria: postmenopausal women (amenorrhoeic for at least one year or were
aged up to 53 years and been receiving HRT in the past for at least six months)
Exclusion criteria: uncontrolled hypertension (diastolic > 100 mmHg), renal impair-
ment (creatinine > 150 µmol/L), previous malignancy, unstable angina, myocardial in-
farction previous six months, hysterectomy or a history of excess alcohol consumption
or taking warfarin or drugs which may interfere with oestrogen metabolism
Diagnostic criteria: amenorrhoeic for at least one year or were aged up to 53 years and
had been receiving HRT in the past for at least six months
Co-morbidities: not stated
Co-medications: not stated
Interventions Number of study centres: 11 centres nationwide
Country/location: UK
Setting: delivered by healthcare professionals from hospital diabetic clinics in the UK
Intervention: oestrogen (17B-oestradiol, 2 mg) and progesterone (norethisterone ac-
etate, 1 mg)
Control: placebo (no details stated)
Treatment before study: participants had been receiving HRT in the past for at least
six months
Outcomes Outcome(s) (as stated in the protocol/registered trial documents):
Primary outcome(s):
Total cholesterol (cholesterol oxidase fully enzymatic assay)
LDL (polyethylene glycol (PEG) precipitation)
HDL (polyethylene glycol (PEG) precipitation)
Triglycerides (lipase/glycerol 3-phosphate oxidase assay)
Fibrinogen (immunoturbidimetric assay)
Body mass index (kg/m2)
Blood pressure (mm Hg)
Secondary outcomes: not stated
Additional outcomes: not stated
Study details After a 6-week run-in period, the study lasted for 12 months
Publication details This study was commercially funded
Stated aim of study “...was to examine the effects of HRT (Kliofem) on cardiovascular risk factors, including
lipid profile, glycaemic control, blood pressure and body weight, in postmenopausal
women with T1DM or T2DM”
Notes Key findings: this study demonstrates that HRT results exert a minimal effect on gly-
caemic control. In relation to cardiovascular risk factors, HRT appears to have a neutral
effect on most, though the effects on HDL warrants further investigation
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Scott 2004 (Continued)
Quote from publication: “None of the interactions between type of diabetes (T1DM
or T2DM) and treatment (Kliofem/placebo) achieved statistical significance for any of
the variables analysed; hence, all results are reported for the total number of diabetics
completing the study”
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Comment: method of concealment is not de-
scribed.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Comment: no information on blinding
method is given.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Variables missing values for the 52-
week visit were replaced using the last observa-
tion carried forward technique ... Where week
0 values were missing, they were replaced by
the week -6 values”
Selective reporting (reporting bias) Low risk Comment: all of the study’s outcomes have
been reported
Other bias High risk Quote: “55 patients withdrew from the study...
main reasonswere adverse effects or persistence
of menopausal symptoms”
Comment: no information is provided detail-
ing the differences in drop-out rate between
type 1 diabetes mellitus and type 2 diabetes
mellitus
HDL: high-density lipoprotein; HRT: hormone replacement therapy; LDL: low-density lipoprotein
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Brown 2001 Not type 1 diabetes participants
Hayward 2001 Not type 1 diabetes participants
Kanaya 2003 Not type 1 diabetes participants
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Overview of study populations
Characteris-
tic
Study ID
Intervention
(s) and com-
parator (s)
[N]
screened /
eligible
[N]
randomised
[N]
safety
[N]
ITT
[N]
finishing study
[%] randomised
participants
finishing study
Scott 2004a Hor-
mone replace-
ment therapy
vs placebo
I: 27
C: 29
T: 56
I: 27
C: 29
T: 56
- - - N/A
Total All interven-
tions
27
All controls 29
All interven-
tions and con-
trols
56
“-” denotes not reported
aData on drop-outs, losses to follow-up and missing data were not reported in the type 1 diabetes mellitus participants
C: comparator; I: intervention; N/A: not applicable
A P P E N D I C E S
Appendix 1. Search strategies
Search terms and databases
Unless otherwise stated, search terms are free text terms.
Abbreviations:
’$’: stands for any character; ’?’: substitutes one or no character; adj: adjacent (i.e. number of words within range of search term); exp:
exploded MeSH; MeSH: medical subject heading (MEDLINE medical index term); pt: publication type; sh: MeSH; tw: text word
The Cochrane Library
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(Continued)
The Cochrane Library
#1 MeSH descriptor Diabetes mellitus, type 1explode all trees
#2 MeSH descriptor Diabetic Ketoacidosis explode all trees
#3 MeSH descriptor Diabetes Complications explode all trees
#4 (IDDM in All Text or T1DM in All Text)
#5 ((insulin* in All Text and depend* in All Text) or insulin?depend* in All Text)
#6 (typ* in All Text and 1 in All Text and adj6 in All Text and diabet* in All Text)
#7 (earl* in All Text and adj6 in All Text and diabet* in All Text)
#8 (auto?immun* in All Text and adj6 in All Text and diabet* in All Text)
#9 ((sudden in All Text and onset in All Text) and adj6 in All Text and diabet* in All Text)
#10 (insulin* in All Text and defic* in All Text and adj6 in All Text and absolut* in All Text)
#11 (acidos* in All Text and adj6 in All Text and diabet* in All Text)
#12 (juvenil* in All Text and adj6 in All Text and diabet* in All Text)
#13 (child* in All Text and adj6 in All Text and diabet* in All Text)
#14 (keto* in All Text and adj6 in All Text and diabet* in All Text)
#15 (labil* in All Text and adj6 in All Text and diabet* in All Text)
#16 (britt* in All Text and adj6 in All Text and diabet* in All Text)
#17 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16)
#18 MeSH descriptor Diabetes insipidus explode all trees
#19 (diabet* in All Text and insipidus in All Text)
#20 (#18 or #19)
#21 (#17 and not #20)
#22 MeSH descriptor Hormone replacement therapy explode all trees
#23 (hormon* in All Text and (replacement in All Text AND therap* in All Text) )
#24 (hormon* in All Text and (replacement in All Text AND intervention* in All Text) )
#25 (#22 or #23 or #24)
#26 #21 and #25
MEDLINE
1. exp Diabetes Mellitus, Type 1/
2. exp Diabetic Ketoacidosis/
3. exp Diabetes Complications/
4. (IDDM or T1DM or T1D).tw,ot.
5. ((“insulin* depend*” or “insulin?depend*”) not (“non-insulin* depend*” or “noninsulindepend*”)).tw,ot.
6. ((“typ? 1” or “typ? I” or “typ?1” or “typ?I”) adj2 diabet*).tw,ot.
7. ((acidos* or juvenil* or child* or keto* or labil* or britt*) adj2 diabet*).tw,ot.
8. ((auto-immun* or autoimmun* or sudden onset) adj2 diabet*).tw,ot.
9. (insulin* defic* adj2 absolut*).tw,ot.
10. or/1-9
11. exp Diabetes Insipidus/
12. diabet* insipidus.tw,ot.
13. 11 or 12
14. 10 not 13
15. exp Hormone Replacement Therapy/
16. hormone replacement*.tw,ot.
17. or/15-16
18. 14 and 17
19. (animals not (animals and humans)).sh.
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(Continued)
20. 17 not 18
21. Limit 20 to RCT
EMBASE
1. exp Insulin Dependent Diabetes Mellitus/
2. exp Diabetic Ketoacidosis/
3. exp Diabetic Retinopathy/ or exp Diabetic Angiopathy/ or exp Diabetic Neuropathy/ or
4. exp Diabetic Nephropathy/
5. (IDDM or T1DM).tw,ot.
6. (insulin$ depend$ or insulin?depend$).tw,ot.
7. ((typ$ 1 or typ$I) adj6 diabet$).tw,ot.
8. ((earl$ or auto?immun$ or sudden onset) adj6 diabet$).tw,ot.
9. (insulin$ defic$ adj6 absolut$).tw,ot.
10. ((acidos$ or juvenil$ or child$ or keto$ or labil$ or britt$) adj6 diabet$).tw,ot
11. or/1-9
12. exp Diabetes Insipidus/
13. diabet$ insipidus.tw,ot.
14. 11 or 12
15. 10 not 13
16. exp hormone substitution/
17. (hormon* adj3 (substitution* or replacement*)).tw,ot.
18. or/15-16
19. 14 and 17
20. limit 18 to human
21. limit 19 to RCT
CINAHL
1. (MH “Diabetes Mellitus, Type 1”)
2. (MH “Diabetic Ketoacidosis”)
3. Diabetes Complications/
4. (IDDM or T1DM or T1D).tw,ot.
5. ((“insulin* depend*” or “insulin?depend*”) not (“non-insulin* depend*” or “non insulindepend*”)).tw,ot.
6. ((“typ? 1” or “typ? I” or “typ?1” or “typ?I”) adj2 diabet*).tw,ot.
7. ((acidos* or juvenil* or child* or keto* or labil* or britt*) adj2 diabet*).tw,ot.
8. ((auto-immun* or autoimmun* or sudden onset) adj2 diabet*).tw,ot.
9. (insulin* defic* adj2 absolut*).tw,ot.
10. or/1-9
11. exp Diabetes Insipidus/
12. diabet* insipidus.tw,ot.
13. 11 or 12
14. 10 not 13
15. exp Hormone Replacement Therapy/
16. hormone replacement*.tw,ot.
17. exp Menopause, Premature/ or exp Menopause/
18. (menopaus$ or postmenopaus$ or perimenopaus$ or premenopaus$).tw,ot.
19. or/15-18
20. 14 and 19
21. limit 18 to female
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(Continued)
22. (animals not (animals and humans)).sh.
23. 19 not 20
PsycINFO
1. (TX+(Diabetes+Mellitus))+OR+(TX+(Type+1)))
2. (TX+(Diabetic+Ketoacidosis))
3. (TX+(Diabetes+Complications))
4. (TX+(IDDM))+OR+(TX+(T1DM))
5. ((TX+(insulin*+AND+depend*))+OR+(TX+(insulin%3fdepend*)))
6. ((TX+(typ*)+AND+1+AND+adj6+AND+diabet*))+OR+((TX+(earl*)+AND+TX+(adj6)+AND+TX+(diabet*)))
7. ((TX+(auto%3fimmun*))+AND+(TX+(adj6))+AND+(TX+(diabet*)))
8. ((TX+(sudden+AND+onset))+AND+(TX+(adj6))+AND+(TX+(diabet*)))
9. ((TX+(insulin*))+AND+(TX+(defic*))+AND+(TX+(adj6))+AND+(TX+(absolut*)))
10. ((TX+(acidos*))+AND+(TX+(adj6))+AND+(TX+(diabet*)))
11. ((TX+(juvenil*))+AND+(TX+(adj6))+AND+(TX+(diabet*)))
12. ((TX+(child*))+AND+(TX+(adj6))+AND+(TX+(diabet*)))
13. ((TX+(keto*))+AND+(TX+(adj6))+AND+(TX+(diabet*)))
14. ((TX+(labil*))+AND+(TX+(adj6))+AND+(TX+(diabet*)))
15. ((TX+(britt*))+AND+(TX+(adj6))+AND+(TX+(diabet*)))))
16. S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15
17. (TX+(diabetes+insipidus)))
18. ((TX+(diabet*))+AND+(TX+(insipidus)))))))
19. S17 OR S18
20. S16 NOT S19
21. ((((MJ+(Hormone+Replacement+Therapy)))
22. ((TX+(hormon*+AND+replacement+AND+therap*)))
23. ((TX+(hormon*+AND+replacement+AND+intervention*))))))
24. S21 OR S22 OR S23
25. S20 AND S24
Appendix 2. Description of interventions
Characteristic
Study ID
Intervention [route, frequency, total dose/day] Comparator [route, frequency, total dose/day]
Scott 2004 Hormone replacement therapy (oestrogen (17B-
oestradiol, 2 mg) and
progesterone (norethisterone acetate, 1 mg))
Placebo (not described)
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Appendix 3. Baseline characteristics
Characteris-
tic
Study ID
Duration of
intervention
(duration of
follow-up)
Participating
population
Age
[mean years
(SD)]
HbA1c
[mean %
(SD)]
BMI
[mean kg/m2
(SD)]
Ethnic
groups
[%]
Duration of
disease
[mean years
(SD)]
Scott 2004 12 months (at
12 months)
55 60 (6) - 28.5 (6.1) - -
Footnotes
“-” denotes not reported
BMI: body mass index; HbA1c: glycosylated haemoglobin A1c; SD: standard deviation
Appendix 4. Matrix of study endpoints
Characteristic Primarya endpoint(s) Secondaryb endpoint(s) Otherc endpoint(s)
Scott 2004 Cardiovascular risk factors (lipid
profile), glycaemic control (fruc-
tosamine), blood pressure, BMI
- -
Footnotes
a,b,as stated in the publication; cnot stated as primary or secondary endpoint(s) in the publication
BMI: body mass index
Appendix 5. Adverse events (I)
Characteris-
tic
Study ID
Deaths
[n]
Adverse
events
[n / %]
Severe/
serious
adverse events
[n / %]
Drop-outs
due
to adverse
events [n / %]
Hospitalisa-
tion
[n / %]
Out-patient
treatment
[n / %]
Hypogly-
caemic
episodes
[n / %]
Scott 2004 - - - - - - -
Footnotes
“-” denotes not reported
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Appendix 6. Adverse events (II)
Characteristic
Study ID
Severe hypoglycaemic
episodes
[n / %]
Definition of severe /
serious hypoglycaemia
Nocturnal
hypoglycaemic
episodes
[n / %]
Symptoms
[n / %]
Scott 2004 - - - -
Footnotes
“-” denotes not reported
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